Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.

Journal for immunotherapy of cancer - 1 Jan 2021

Rose April A N, Armstrong Susan M, Hogg David, Butler Marcus O, Saibil Samuel D, Arteaga Diana P, Pimentel Muniz Thiago, Kelly Deirdre, Ghazarian Danny, King Ian, Kamil Zaid Saeed, Ross Kendra, Spreafico Anna

Abstract excerpt

PURPOSE: Anti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma. We assessed whether biologic subtype according to primary tumor type or genomic subtype can function as predictive biomarkers for anti-PD1±anti-CTLA4 ICI in patients with advanced melanoma. METHODS: We performed a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Ipilimumab

Share to Melanoma

Share to Neoplasm Metastasis

Share to Nivolumab

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 33483342
DOI: 10.1136/jitc-2020-001642
PMCID: PMC7831745

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.PMID 33483342Read ↗

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.Semantic proximity Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanomaSemantic proximity Read ↗

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.Semantic proximity Read ↗

Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.Semantic proximity Read ↗

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Semantic proximity Read ↗

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.Semantic proximity Read ↗

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.Semantic proximity Read ↗

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary MelanomasSemantic proximity Read ↗

Predicting response and resistance to immune checkpoint blockade and surgery in melanoma patientsSemantic proximity Read ↗

Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An UpdateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.